BOSTON, Sept. 17, 2025 - Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, and Berlin-based femtech startup Frieda Health have announced the successful completion of their clinical trial for a digital therapeutic to treat symptoms of menopausal and climacteric states. This open-label pilot study evaluated the Frieda Menova app—Frieda Health's proprietary digital therapeutic that integrates cognitive behavioral therapy (CBT)—for its effectiveness in alleviating menopausal symptoms, including vasomotor disturbances, sleep disruption, and psychological distress. This was the first clinical trial to evaluate a digital therapeutic utilizing CBT for the treatment of menopause symptoms.
Women experience a wide range of psychological, somatic, and vasomotor symptoms during menopause. The current standard-of-care to treat severe menopause symptoms is hormone replacement therapy (HRT), however, many women choose not to receive HRT due to increased health risks such as breast cancer and stroke. CBT has proven to be an effective alternative treatment option in improving menopause symptoms like hot flushes, sleep disturbances, and depressed mood.
Frieda Health leveraged an innovative novel trial design that allowed menopausal women to participate in the study remotely across Germany, expanding access to the study typically reserved for study site centers.
The study enrolled 100 participants with a physician-confirmed natural menopause diagnosis and clinically significant symptoms. Lindus Health provided end-to-end oversight of the trial—covering regulatory submissions, participant recruitment, monitoring, data management, and statistical analysis. Serving as the sole virtual site, Lindus Health also deployed its novel internal central recruitment capabilities to identify and engage participants through targeted social media campaigns. Screening and enrollment were conducted via telemedicine visits, making participation more efficient and accessible.
"Half the global population will experience menopause and it is important to understand this stage of life," said Dr. Anita Phung, Medical Monitor at Lindus Health. "We're excited to see new interventions for menopause on the horizon that offer alternatives to traditional HRT, allowing treatment approaches to be tailored to individual preferences. We can't wait to see the results of the trial."
"Our work with Lindus marks major development in closing the care gap for women with menopause," said Dr. Kai Schulze-Wundling, Co-founder and Chief Medical Officer at Frieda Health. "There are credible digital solutions to managing diabetes, mental health conditions, and numerous other common indications—it's time we add menopause to the list."
The Frieda Menova app produced large, clinically meaningful and statistically significant reductions in menopausal symptom burden compared to standard of care, reinforcing the promise of digital CBT for menopause and guiding further development.
Lindus Health is the anti-CRO running radically faster, more reliable clinical trials for life science pioneers—bringing ground-breaking treatments to patients more quickly. By aligning incentives through fixed-price, milestone-based contracts, combining a world-class clinical operations team with a unique software platform, and leveraging access to over 40 million Electronic Health Records, Lindus Health delivers trials designed for speed, reliability, and impact.
The company removes the biggest bottleneck in healthcare—clinical trials—through end-to-end study execution powered by technology and forward-thinking approaches to clinical operations. Lindus Health works with leading biotech, medical device, diagnostics, and consumer health companies to accelerate the development of innovative therapies and products. Its impact has been recognized with prestigious accolades, including the Fierce Biotech CRO Awards for Outstanding Patient Recruitment and Retention and inclusion in the PM360 Elite 100.
To date, Lindus Health has delivered trials across the US, UK, and Europe in conditions ranging from diabetes and asthma to major depressive disorder, hypertension, and chronic fatigue syndrome. The company has raised over $80M from investors including Balderton, Peter Thiel, Creandum, Firstminute Capital, and Seedcamp.
Frieda Health is a CE-marked (EU MDR Class I) digital menopause clinic that systematically assesses symptoms, delivers evidence-based guidance - grounded in CBT and lifestyle medicine - and connects users to physician-supervised care when needed. Frieda's Menova therapy is provided via the Frieda app and is intended to reduce the burden of vasomotor symptoms, sleep problems, and stress.
Frieda Health is committed to clinical evidence. The Frieda Menova trial builds on prior trials showing that cognitive-behavioral approaches - delivered in person or digitally - can meaningfully lessen the impact of hot flushes/night sweats and improve quality of life.
Looking ahead, Frieda Health will expand into additional high-need topics in women's health and explicitly link our programs to Female Longevity—helping women extend their healthy years ("healthspan") through prevention, risk-reduction, and sustained self-management starting at midlife.
Jodi Perkins
New Study from Lindus Health Finds Nearly Half of Consumers Will Abandon Health Products Lacking Clear Scientific Evidence
Discover consumer purchasing motivations from Lindus Health's latest market research.
